Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844519 · ClinicalTrials.gov registry record · Phase 3
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
A Phase 3 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 3
- Development phase
- 52
- Enrollment target
NCT00844519 is a Phase 3 study that has completed, run by University of California, San Francisco. The registered enrollment target is 52 participants.
The verdict
NCT00844519, a Phase 3 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the potentially beneficial aspects of CCR5 inhibition on inflammation and endothelial function as measured by brachial artery reactivity in antiretroviral treated HIV patients with an undetectable viral load.
Interventions
- DRUG placebo
- DRUG Maraviroc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00844519
The ClinicalTrials.gov registry entry for NCT00844519 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00844519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00844519 about?
NCT00844519 is a clinical study titled "Effect of Maraviroc on Endothelial Function in HIV-Infected Patients". The purpose of this study is to determine the potentially beneficial aspects of CCR5 inhibition on inflammation and endothelial function as measured by brachial artery reactivity in antiretroviral treated HIV patients with an undetectable viral load.
What is the current status of trial NCT00844519?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 52 participants. The study started on 2010-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00844519?
The interventions under investigation include: placebo (DRUG), Maraviroc (DRUG).
Who is sponsoring clinical trial NCT00844519?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.